Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysis
Ackermann C, Gueller U, Jochum W, Schmied B, Warschkow R. The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysis. Int J Colorectal Dis 2018
07.06.2018The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysis
07.06.2018Int J Colorectal Dis 2018
Ackermann Christoph Jakob, Gueller Ulrich, Jochum Wolfram, Schmied Bruno, Warschkow Rene
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Gillison M, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris R. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist 2018; 23:1079-1082.
04.06.2018CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
04.06.2018Oncologist 2018; 23:1079-1082
Gillison Maura L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Monga Manish, Lynch Mark, Li Li, Ferris Robert L
Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer
Siano M, Jarisch N, Jörger M, Espeli V. Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer. Anticancer Res 2018; 38:3725-3729.
01.06.2018Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer
01.06.2018Anticancer Res 2018; 38:3725-3729
Siano Marco, Jarisch Nadine, Jörger Markus, Espeli Vittoria
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
Wirsching H, Riklin C, Felsberg J, Roth P, Jones D, Pfister S, Rushing E, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, von Moos R, Caparrotti F, Tabatabai G, Roelcke U, Hottinger A, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Weller M. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann Oncol 2018; 29:1423-1430.
01.06.2018Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
01.06.2018Ann Oncol 2018; 29:1423-1430
Wirsching H-G, Riklin C, Felsberg J, Roth P, Jones D T W, Pfister S, Rushing E J, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, von Moos R, Caparrotti F, Tabatabai G, Roelcke U, Hottinger A F, Jörger F, Schmid A, Plasswilm Ludwig, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger Thomas, Weller M
Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
Sajic T, Claassen M, Gillessen Sommer S, Omlin A, Malander S, Niméus E, Friedrich B, Blattmann P, Chen R, Brentnall T, Pan S, Sethi A, Hüttenhain R, Schiess R, Williams E, Surinova S, Arvaniti E, Liu Y, Aebersold R. Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS. Cell Rep 2018; 23:2819-2831.e5.
29.05.2018Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
29.05.2018Cell Rep 2018; 23:2819-2831.e5
Sajic Tatjana, Claassen Manfred, Gillessen Sommer Silke, Omlin Aurelius, Malander Susanne, Niméus Emma, Friedrich Betty, Blattmann Peter, Chen Ru, Brentnall Teresa A, Pan Sheng, Sethi Atul, Hüttenhain Ruth, Schiess Ralph, Williams Evan G, Surinova Silvia, Arvaniti Eirini, Liu Yansheng, Aebersold Ruedi
Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial
Siano M, Espeli V, Mach N, Bossi P, Licitra L, Ghielmini M, Frattini M, Canevari S, De Cecco L. Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. Oral Oncol 2018; 82:144-151.
28.05.2018Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial
28.05.2018Oral Oncol 2018; 82:144-151
Siano Marco, Espeli Vittoria, Mach Nicolas, Bossi Paolo, Licitra Lisa, Ghielmini Michele, Frattini Milo, Canevari Silvana, De Cecco Loris
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
Fasching P, Huober J, Liedtke C, Weinshilboum R, Wang L, Ingle J, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, von Minckwitz G, Fehm T, Blohmer J, Costa S, Loibl S, Hu C, Hart S, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Couch F. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018; 36:2281-2287.
23.05.2018BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
23.05.2018J Clin Oncol 2018; 36:2281-2287
Fasching Peter A, Huober Jens, Liedtke Cornelia, Weinshilboum Richard M, Wang Liewei, Ingle James N, Müller Volkmar, Nekljudova Valentina, Weber Karsten E, Rack Brigitte, Rübner Matthias, von Minckwitz Gunter, Fehm Tanja, Blohmer Jens-Uwe, Costa Serban Dan, Loibl Sibylle, Hu Chunling, Hart Steven N, Shimelis Hermela, Moore Raymond, Schem Christian, Tesch Hans, Untch Michael, Hilfrich Jörn, Rezai Mahdi, Gerber Bernd, Couch Fergus J
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
Sumanasuriya S, Luo J, Mehra N, Olmos D, Scher H, Soule H, Stoecklein N, Terstappen L, Waugh D, Lorente D, Lolkema M, Omlin A, Armstrong A, Attard G, Chi K, Bevan C, Shibakawa A, IJzerman M, De Laere B, de Bono J. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. Eur Urol Oncol 2018; 1:151-159.
15.05.2018Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
15.05.2018Eur Urol Oncol 2018; 1:151-159
Sumanasuriya Semini, Luo Jun, Mehra Niven, Olmos David, Scher Howard, Soule Howard, Stoecklein Nikolas H, Terstappen Leon W M M, Waugh David, Lorente David, Lolkema Martijn, Omlin Aurelius, Armstrong Andrew, Attard Gerhardt, Chi Kim N, Bevan Charlotte L, Shibakawa Aki, IJzerman Maarten J, De Laere Bram, de Bono Johann S
Genomic Features of Response to Combination Immunotherapy in Lung Cancer
Früh M, Peters S. Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell 2018; 33:791-793.
14.05.2018Genomic Features of Response to Combination Immunotherapy in Lung Cancer
14.05.2018Cancer Cell 2018; 33:791-793
Früh Martin, Peters Solange
FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.
Schneider P, Eshmuminov D, Rordorf T, Vetter D, Veit-Haibach P, Weber A, Bauerfeind P, Samaras P, Lehmann K. FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC cancer 2018; 18:548.
09.05.2018FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.
09.05.2018BMC cancer 2018; 18:548
Schneider Paul M, Eshmuminov Dilmurodjon, Rordorf Tamara, Vetter Diana, Veit-Haibach Patrick, Weber Achim, Bauerfeind Peter, Samaras Panagiotis, Lehmann Kuno
Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer
Gong J, Omlin A, Pal S, Hsu J, Tombal B, Sydes M, Gillessen Sommer S. Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer. Eur Urol 2018
03.05.2018Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer
03.05.2018Eur Urol 2018
Gong Jun, Omlin Aurelius, Pal Sumanta K, Hsu J, Tombal Bertrand, Sydes Matthew R, Gillessen Sommer Silke
Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma
Fischer S, Ali O, Jochum W, Kluckert J, Flatz L, Siano M. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. Oncol Res Treat 2018; 41:391-394.
03.05.2018Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma
03.05.2018Oncol Res Treat 2018; 41:391-394
Fischer Stefanie, Ali Omar H, Jochum Wolfram, Kluckert Jörg-Thomas, Flatz Lukas, Siano Marco
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N, Waage A, Beksac M, Mellqvist U, Engelhardt M, Caers J, Driessen C, Bladé J, Mateos M, Garderet L, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hájek R, Mohty M, Cavo M, Dimopoulos M, San-Miguel J, Terpos E, Zweegman S, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2018
02.05.2018Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
02.05.2018Leukemia 2018
Ludwig Heinz, Cook Gordon, Leleu Xavier, Goldschmidt Hartmut, Jackson Graham, Kaiser Martin, Weisel Katja, van de Donk Niels W C J, Waage Anders, Beksac Meral, Mellqvist Ulf H, Engelhardt Monika, Caers Jo, Driessen Christoph, Bladé Joan, Mateos Maria-Victoria, Garderet Laurent, Delforge Michel, Facon Thierry, Einsele Hermann, Gay Francesca, Moreau Philippe, Avet-Loiseau Hervé, Boccadoro Mario, Hájek Roman, Mohty Mohamad, Cavo Michele, Dimopoulos Meletios A, San-Miguel Jesús F, Terpos Evangelos, Zweegman Sonja, Sonneveld Pieter
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
STAMPEDE Investigators, Protheroe A, Peedell C, Parikh O, O'Sullivan J, Nikapota A, Lester J, McLaren D, Hughes R, Gilbert D, Gibbs S, Rudman S, Shaffer R, Sheehan D, James N, Parmar M, Wagstaff J, Varughese M, Tsang D, Tolan S, Sundar S, Strebel R, Srihari N, Simms M, Gale J, Ford D, Evans L, Malik Z, Gillessen Sommer S, Cross W, Chowdhury S, Attard G, de Bono J, Dearnaley D, Clarke N, Mason M, Spears M, Jones R, Parker C, Ritchie A, Choudhury A, Chakraborti P, Capaldi L, Brock S, Birtle A, Gilson C, Amos C, Matheson D, Millman R, Russell J, Sydes M. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018; 29:1235-1248.
01.05.2018Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
01.05.2018Ann Oncol 2018; 29:1235-1248
STAMPEDE Investigators, Protheroe A, Peedell C, Parikh O, O'Sullivan J, Nikapota A, Lester J F, McLaren D, Hughes R, Gilbert D C, Gibbs S, Rudman S M, Shaffer R, Sheehan D, James N D, Parmar M K B, Wagstaff J, Varughese M, Tsang D, Tolan S, Sundar S, Strebel R, Srihari N, Simms M, Gale J, Ford D, Evans L, Malik Z I, Gillessen Sommer Silke, Cross W, Chowdhury S, Attard G, de Bono J S, Dearnaley D P, Clarke N W, Mason M D, Spears M R, Jones R, Parker C C, Ritchie A W S, Choudhury A, Chakraborti P, Capaldi L, Brock S, Birtle A, Gilson C, Amos C, Matheson D, Millman R, Russell J M, Sydes M R
Immune checkpoint inhibitors and small cell lung cancer: what's new?
Schmid S, Früh M. Immune checkpoint inhibitors and small cell lung cancer: what's new?. J Thorac Dis 2018; 10:S1503-S1508.
01.05.2018Immune checkpoint inhibitors and small cell lung cancer: what's new?
01.05.2018J Thorac Dis 2018; 10:S1503-S1508
Schmid Sabine, Früh Martin
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial
Fitzal F, Gnant M, Greil R, Soelkner L, Schrenk P, Bartsch R, Singer C, Balic M, Hubalek M, Steger G, Knauer M, Bjelic-Radisic V, ABCSG. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg 2018
24.04.2018Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial
24.04.2018Ann Surg 2018
Fitzal Florian, Gnant Michael, Greil Richard, Soelkner Lidija, Schrenk Peter, Bartsch Rupert, Singer Christian, Balic Marija, Hubalek Michael, Steger Günther, Knauer Michael, Bjelic-Radisic Vesna, ABCSG
Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?
Isensee G, Péporté A, Müller J, Schmid S, Gillessen Sommer S, Omlin A. Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?. Clin Genitourin Cancer 2018; 16:349-354.
23.04.2018Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?
23.04.2018Clin Genitourin Cancer 2018; 16:349-354
Isensee Gesa, Péporté Anne, Müller Joachim, Schmid Sabine, Gillessen Sommer Silke, Omlin Aurelius
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
Dowsett M, Sestak I, Regan M, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol 2018; 36:1941-1948.
20.04.2018Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
20.04.2018J Clin Oncol 2018; 36:1941-1948
Dowsett Mitch, Sestak Ivana, Regan Meredith M, Dodson Andrew, Viale Giuseppe, Thürlimann Beat, Colleoni Marco, Cuzick Jack
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison M. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018; 81:45-51.
17.04.2018Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
17.04.2018Oral Oncol 2018; 81:45-51
Ferris Robert L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Docampo Lara Carmen Iglesias, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Lynch Mark, Jayaprakash Vijayvel, Li Li, Gillison Maura L
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study
Gordon J, Cox M, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl B, Cherhroudi C, Pignata S, Battaglia M, Buonerba C, Pond G, Crona D, Gillessen Sommer S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke J, Bosso D, Milowsky M, Witek M, Di Lorenzo G. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget 2018; 9:19861-19873.
13.04.2018Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study
13.04.2018Oncotarget 2018; 9:19861-19873
Gordon Jacob A, Cox Michael E, De Placido Pietro, Ribera Dario, Omlin Aurelius, Buonocore Gaetano, Chi Kim, Kollmannsberger Christian, Khalaf Daniel, Facchini Gaetano, Sonpavde Guru, De Placido Sabino, Eigl Bernhard J, Cherhroudi Cyrus, Pignata Sandro, Battaglia Michele, Buonerba Carlo, Pond Gregory, Crona Daniel, Gillessen Sommer Silke, Lucarelli Giuseppe, Rossetti Sabrina, Dorff Tanya, Artale Salvatore, Locke Jennifer A, Bosso Davide, Milowsky Matthew Ivan, Witek Mira Sofie, Di Lorenzo Giuseppe